APA (7th ed.) Citation

E, C., R, M., G, E., MM, V., CN, C., JA, M., . . . P, P. (2026). Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort. Cephalalgia : an international journal of headache, 46(6), 3331024261440370. https://doi.org/10.1177/03331024261440370

Chicago Style (17th ed.) Citation

E, Caronna, et al. "Is Achieving Higher Standards in Real-world Migraine Care Feasible with Anti-CGRP Monoclonal Antibodies Preventive Therapies?: Insights from the EUREkA Cohort." Cephalalgia : An International Journal of Headache 46, no. 6 (2026): 3331024261440370. https://doi.org/10.1177/03331024261440370.

MLA (9th ed.) Citation

E, Caronna, et al. "Is Achieving Higher Standards in Real-world Migraine Care Feasible with Anti-CGRP Monoclonal Antibodies Preventive Therapies?: Insights from the EUREkA Cohort." Cephalalgia : An International Journal of Headache, vol. 46, no. 6, 2026, p. 3331024261440370, https://doi.org/10.1177/03331024261440370.